ABSTRACT
Rationale Impaired baseline lung function is associated with mortality after allogeneic hematopoietic cell transplantation (HCT). Limited knowledge of the molecular pathways that characterize pre-transplant lung function has hindered the development of lung-targeted interventions.
Objectives To elucidate the biologic and microbiologic correlates of impaired lung function in pediatric allogeneic HCT candidates.
Methods Between 2005-2016, 104 patients with malignant and non-malignant disorders ages 4-19 years underwent paired pulmonary function testing (PFT) and bronchoalveolar lavage (BAL) a median of 1-2 weeks prior to allogeneic transplant in Utrecht, the Netherlands. Cryopreserved BAL underwent RNA sequencing followed by alignment to microbial and human reference genomes for microbiome and gene expression analyses.
Measurements and Main Results Abnormal pulmonary function was recorded in more than half the cohort, consisted most commonly of restriction and impaired diffusion, and was associated with both all-cause and lung-injury related mortality after HCT. BAL microbiome depletion of commensal supraglottic taxa such as Haemophilus and enrichment of nasal and skin taxa such as Staphylococcus were associated with worse measures of lung capacity and gas diffusion. In addition, impaired lung capacity and diffusion were also associated with gene expression signatures of alveolar epithelial proliferation, epithelial-mesenchymal transition, and downregulated immunity, suggesting a post-injury pro-fibrotic response. Detection of microbial depletion and abnormal epithelial gene expression in BAL enhanced the prognostic utility of pre-HCT PFTs for the outcome of post-HCT mortality.
Conclusions These findings suggest a novel and potentially actionable connection between microbiome depletion, alveolar injury, and pulmonary fibrosis in the pathogenesis of pre-HCT lung dysfunction.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NHLBI K23HL146936, NICHD K12HD000850, American Thoracic Society Foundation Grant
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University Medical Center Utrecht IRB #05/143 and #11/063
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Zinter MS and Versluys BA share first authorship.
↵# DeRisi JL and Boelens JJ share senior authorship.
Funding: National Marrow Donor Program Amy Strelzer Manasevit Grant (MSZ), NICHD K12HD000850 (MSZ), NHLBI K23HL146936 (MSZ), American Thoracic Society Foundation Grant (MSZ), NHLBI R01HL134828 (MAM), NHLBI R35HL140026 (MAM), Chan Zuckerberg Biohub (JLD).
Data Availability
Data Sharing Statement: Sequencing files are available through dbGaP study accession phs002208.v1.p1.